Antibodies directed against influenza

Patent metadata

Field	Value
Publication number	US-9321829-B2
Application number	US-201214350632-A
Country	US
Kind code	B2
Filing date	Oct 18, 2012
Priority date	Oct 18, 2011
Publication date	Apr 26, 2016
Grant date	Apr 26, 2016

Abstract

Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided.

First claim

We claim:

1. A non-naturally occurring chimeric monoclonal antibody, wherein the monoclonal antibody comprises a heavy chain variable domain and a light chain variable domain,
wherein the heavy chain variable domain comprising the amino acid sequence set forth as SEQ ID NO: 3, the amino acid sequence set forth as SEQ ID NO: 5, and the amino acid sequence set forth as SEQ ID NO: 7 and the light chain variable domain comprising the amino acid sequence set forth as SEQ ID NO: 13, the amino acid sequence set forth as SEQ ID NO: 15, and the amino acid sequence set forth as SEQ ID NO: 17, and
wherein the monoclonal antibody specifically binds hemagglutinin (HA) of at least two of H1N1 and H5N1.

2. The non-naturally occurring chimeric monoclonal antibody of claim 1 , wherein the monoclonal antibody specifically binds HA of H3N2.

3. The non-naturally occurring chimeric monoclonal antibody of claim 1 , wherein the heavy chain variable domain comprises
an amino acid sequence set forth as SEQ ID NO: 9.

4. The non-naturally occurring chimeric monoclonal antibody of claim 1 , wherein the light chain variable domain comprises
an amino acid sequence set forth as SEQ ID NO: 19.

5. The non-naturally occurring chimeric monoclonal antibody of claim 1 , wherein the antibody is an IgG, IgM or IgA.

6. The non-naturally occurring chimeric monoclonal antibody of claim 1 , wherein the antibody is labeled.

7. The non-naturally occurring chimeric monoclonal antibody of claim 6 , wherein the label is a fluorescent, enzymatic, or radioactive label.

8. A composition comprising the non-naturally occurring chimeric antibody of claim 1 and a pharmaceutically acceptable carrier.

9. A purified nucleic acid molecule encoding the non-naturally occurring chimeric monoclonal antibody of claim 1 .

10. The purified nucleic acid molecule of claim 9 , comprising a nucleotide sequence set forth as
SEQ ID NO: 8.

11. An expression vector comprising a nucleic acid comprising SEQ ID NO: 8.

Assignees

• Ahmed Rafi
• Wrammert Jens
• Wilson Patrick C
• Univ Emory

Inventors

• Ahmed Rafi
• Wrammert Jens
• Wilson Patrick C

Classifications

• G01N33/56983

  Viruses · CPC title

• C07K2317/54

  F(ab')2 · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title